Jun 23,2023

A Dual Function Glucose Sensing Insulin Delivery Technology Is Presented at the 83rd Scientific Sessions of the American Diabetes Association

One of the studies presented at the ADA conference in San Diego, CA was about the SynerG, a dual-function glucose sensing-insulin delivery device developed by Pacific Diabetes Technologies that simplifies diabetes management. The SynerG glucose sensor has a warm-up time of less than 30 min and also synchronizes replacement schedules for insulin delivery and glucose measurement functions. Feasibility of a Prototype Dual Function Glucose Sensing Insulin Delivery Cannula in People with Type 1 Diabetes, showed the feasibility of the first single through-the-skin device combining glucose sensing and insulin delivery functions (SynerG). The study enrolled 24 adults with type 1 diabetes on insulin pump therapy (IPT). The device was inserted subcutaneously in the anterior abdomen and attached to the pump, following a 48-hour run-in using a commercially available infusion set with a study pump. Findings for 24 participants indicate that insulin did not interfere with the function of the glucose sensor and demonstrated accuracy in the measurement of glucose. In addition, insulin was delivered reliably to participants.

CLINICAL STUDY

#cgm

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jun 23,2023

Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users

Medtronic presented new clinical and real-world data on the MiniMed™ 780G system at the 83rd American Diabetes Association Scientific Sessions. The data showed that the system's Meal Detection™ technology supported Time in Range outcomes exceeding consensus guidelines of 70% and helped reduce hyperglycemia. A study also demonstrated that simplified meal announcements using the system helped users maintain glycemic targets and reduce hyperglycemia. Real-world evidence showed strong performance in children, and data on the Medtronic Extended Infusion™ Set demonstrated reduced user burden through less frequent set changes.

CLINICAL STUDY

#insulin pump

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jun 21,2023 TOP STORY

Real-World Data Demonstrate the Potential for Rapid and Durable Improvement in Glycemic Control for People with Insulin-requiring Diabetes Using the Bigfoot Unity® System

Bigfoot Biomedical today announced the publication of a six-month retrospective analysis of real-world use data of the Bigfoot Unity® System in the American Diabetes Association's (ADA) journal, Clinical Diabetes. In this initial 58-person cohort, results demonstrate the potential of the Bigfoot Unity System to support rapid and durable improvement in glucose control in people with diabetes who use multiple daily injections of insulin.

CLINICAL STUDY

#cgm

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 10,2023

New Data at AHS Annual Meeting Demonstrate Substantial Results for Patients Using Neurolief's Digital Therapeutics Technology to Treat Migraine

Neurolief, a medical neurotechnology innovator, today announced new data released at the 65th Annual Scientific Meeting hosted by the American Headache Society (June 15-18, 2023, Austin, TX). The real-world, open label analysis presents clinically meaningful data on both the acute treatment and prevention of migraine. Relivion MG is a novel wearable digital therapeutic neurostimulation system, intended to treat migraine and reduce the need for drug therapies. Neurolief's post-hoc analysis on 16 subjects with high frequency episodic or chronic migraine decreased Mean Monthly Migraine Days (MMD) by 75%, from 17.8 days per month at baseline to 4.8 days at the end of the third treatment month.

CLINICAL STUDY

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 21,2023

Clinical Study Evaluated Safety of Using Nerivio® for Treating Migraine in Pregnant Women

Theranica, a prescribed digital therapeutics company, announced the results of a study recently published in Headache demonstrating the safety of the Nerivio® migraine bioband, a novel Remote Electrical Neuromodulation (REN) wearable, as a drug-free treatment for pregnant women with migraine. The controlled study (NCT05464069) consisted of a retrospective survey of women with migraine between 18 - 45 years of age who were pregnant during the study period. Participants in the REN (Nerivio) group (59 women) used Nerivio for at least 3 treatments during the study pregnancy period, while participants in the control group (81 women) treated with various standard care treatments during pregnancy, except for Nerivio. The study found no statistically significant differences in critical pregnancy outcomes between women with migraine who used the Nerivio migraine bioband during pregnancy throughout three months postpartum, and those who did not use the device during this period. This demonstrates the Nerivio migraine bioband's safety as a migraine treatment for pregnant women while reinforcing its efficacy as seen in previous studies.

CLINICAL STUDY

#pdt

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Jun 20,2023

New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

Veracyte, Inc. announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology. In addition, findings from an analytical validity study presented at the meeting show that the Afirma TERT promoter mutation test performs with high analytical sensitivity and specificity. During the conference there were 3 different study results from the Afirma molecular testing that were presented. “These data demonstrate that our Afirma molecular testing capabilities and genomic-profile database are valuable tools that can help researchers better understand the genomic underpinnings of thyroid nodules and cancer,” said Joshua Klopper, M.D., Veracyte’s medical director of Endocrinology. “Additionally, our findings reinforce the performance of our TERT promoter mutation test, which we recently began offering with our Afirma Genomic Sequencing Classifier to help advance patient care.” Veracyte’s flagship Afirma GSC was developed with RNA whole-transcriptome sequencing and machine learning technology and helps physicians identify patients with benign thyroid nodules among those whose fine needle aspiration (FNA) biopsy results are indeterminate by cytopathology so that they can potentially avoid unnecessary thyroid surgery.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 15,2023 TOP STORY

Digital therapeutic to improve cancer-related well-being: a pilot randomized controlled trial

This randomized waitlist controlled pilot study aimed to evaluate the feasibility and preliminary efficacy of Mika, an app-based digital therapeutic intervention hypothesized to improve management and the support of cancer patients. Patients with gynecological malignancies undergoing post-operative or routine outpatient chemotherapy were randomized (5:2) into intervention (Mika plus treatment-as-usual) and control (treatment-as-usual alone). Feasibility outcomes including dropout rate, reasons for dropout, and intervention adherence, as well as efficacy outcomes including depression, fatigue, and health literacy were assessed at baseline, 4, 8, and 12 weeks. Seventy participants (intervention group, n=50; control group, n=20) with gynecological cancer (ovarian, cervical, and endometrial) were randomized. The dropout rate increased from 15.7% (11/70) between baseline and week 4 to 37.1% (26/70) between weeks 8 and 12. Primary reasons for dropout were death (n=10) and health status deterioration (n=11). Participants in the intervention group showed significant intra-individual reductions in depressive symptoms by 42% (d=0.85) and fatigue symptoms by 23.1% (d=0.5) from baseline to 12 weeks

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 15,2023 TOP STORY

Digital therapeutic to improve cancer-related well-being: a pilot randomized controlled trial

This randomized waitlist controlled pilot study aimed to evaluate the feasibility and preliminary efficacy of Mika, an app-based digital therapeutic intervention hypothesized to improve management and the support of cancer patients. Patients with gynecological malignancies undergoing post-operative or routine outpatient chemotherapy were randomized (5:2) into intervention (Mika plus treatment-as-usual) and control (treatment-as-usual alone). Feasibility outcomes including dropout rate, reasons for dropout, and intervention adherence, as well as efficacy outcomes including depression, fatigue, and health literacy were assessed at baseline, 4, 8, and 12 weeks. Seventy participants (intervention group, n=50; control group, n=20) with gynecological cancer (ovarian, cervical, and endometrial) were randomized. The dropout rate increased from 15.7% (11/70) between baseline and week 4 to 37.1% (26/70) between weeks 8 and 12. Primary reasons for dropout were death (n=10) and health status deterioration (n=11). Participants in the intervention group showed significant intra-individual reductions in depressive symptoms by 42% (d=0.85) and fatigue symptoms by 23.1% (d=0.5) from baseline to 12 weeks

CLINICAL STUDY

#mobile app

#dtx

View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Belong Announces Two Studies Based on RWD at ASCO 2023

Belong.Life has announced that the American Society of Clinical Oncology (ASCO) has published two abstracts in its 2023 Annual Meeting Abstract Book based on data aggregated from the Belong Beating Cancer Together app. The first study (abstract 6592) examined the prevalence of restrictive behavioral practices among cancer patients, analyzing restrictions related to interactions with others, visiting public places and more. The second study (abstract e18774) explored patients’ awareness of the heightened risk of developing a cancer associated thrombosis (CAT) event, a potentially fatal complication in which the pro-coagulation properties in cancer cells along with anti-cancer treatments contribute to the development of blood clots. “Most quality-of-life assessments used today do not measure patients’ ability to maintain normal daily activities during treatment, rather they focus on rigid health-related criteria,” explained Belong.Life Medical Director and Co-author of the study, Dr. Daniel Vorobiof, "This study highlights for pharmaceutical companies, medical researchers and clinical investigators the importance of including real-life quality of life assessments as additional endpoints in clinical trials.”

CLINICAL STUDY

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 14,2023 TOP STORY

Lark Health Announces the Results from Cost Savings Study in DPP

Lark Health announced two new research studies demonstrating the effectiveness of diabetes prevention programs (DPP) and cardiac self-efficacy (CSE). The study, published in Obesity Science and Practice and titled, "Weight Loss and Modeled Cost Savings in a Digital Diabetes Prevention Program," confirms that Lark's scalable, AI-based DPP can reduce staffing needs and shows cost savings for DPPs delivered via other modalities (e.g., in-person, hybrid). Significant cost savings was also calculated by the findings. The estimated medical cost savings for 11,976 members who achieved weight loss and participation outcomes was $12,957,073.

CLINICAL STUDY

#coaching

#dtx

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY